TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02555852

Intervention type: DRUG
Intervention: esomeprazole
Description: Exposure to esomeprazole (ATC A02BC05, B01AC56, M01AE52, A02BD06) will be defined as a prescription for esomeprazole on the same day as a ≥ 30 day NSAID prescription.

Intervention type: DRUG
Intervention: omeprazole
Description: Exposure to omeprazole (ATC A02BC01, A02BD01) will be defined as a prescription for omeprazole on the same day as a ≥ 30 day NSAID prescription.

Intervention type: DRUG
Intervention: pantoprazole
Description: Exposure to pantoprazole (ATC A02BC02, A02BD04) will be defined as a prescription for pantoprazole on the same day as a ≥ 30 day NSAID prescription.

Intervention type: DRUG
Intervention: lansoprazole
Description: Exposure to lansoprazole (ATC A02BC03, A02BD07, A02BD03, A02BD02) will be defined as a prescription for lansoprazole on the same day as a ≥ 30 day NSAID prescription.

Intervention type: DRUG
Intervention: rabeprazole
Description: Exposure to rabeprazole (ATC A02BC04) will be defined as a prescription for rabeprazole on the same day as a ≥ 30 day NSAID prescription.

Intervention type: DRUG
Intervention: cimetidine
Description: Exposure to cimetidine (ATC A02BA01) will be defined as a prescription for cimetidine on the same day as a ≥ 30 day NSAID prescription.

Intervention type: DRUG
Intervention: ranitidine
Description: Exposure to ranitidine (A02BA02) will be defined as a prescription for ranitidine on the same day as a ≥ 30 day NSAID prescription.

Intervention type: DRUG
Intervention: famotidine
Description: Exposure to famotidine (A02BA03) will be defined as a prescription for famotidine on the same day as a ≥30 day NSAID prescription.

Intervention type: DRUG
Intervention: nizatidine
Description: Exposure to nizatidine (A02BA04) will be defined as a prescription for nizatidine on the same day as a ≥ 30 day NSAID prescription.

Intervention type: DRUG
Intervention: niperotidine
Description: Exposure to niperotidine (A02BA05) will be defined as a prescription for niperotidine on the same day as a ≥ 30 day NSAID prescription.

Intervention type: DRUG
Intervention: roxatidine
Description: Exposure to roxatidine (A02BA06) will be defined as a prescription for roxatidine on the same day as a ≥ 30 day NSAID prescription.

Intervention type: DRUG
Intervention: ranitidine bismuth citrate
Description: Exposure to ranitidine bismuth citrate (A02BA07) will be defined as a prescription for ranitidine bismuth citrate on the same day as a ≥ 30 day NSAID prescription.

Intervention type: DRUG
Intervention: lafutidine
Description: Exposure to lafutidine (A02BA08) will be defined as a prescription for lafutidine on the same day as a ≥ 30 day NSAID prescription.

Intervention type: DRUG
Intervention: cimetidine combinations
Description: Exposure to cimetidine combinations (A02BA51) will be defined as a prescription for cimetidine combinations on the same day as a ≥ 30 day NSAID prescription.

Intervention type: DRUG
Intervention: famotidine combinations
Description: Exposure to famotidine combinations (A02BA53) will be defined as a prescription for famotidine combinations on the same day as a ≥ 30 day NSAID prescription.
Study: NCT02432326

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BBI503
Description: The BBI503 starting dose is 200 mg once daily. Dose at modification level 1 to 3 will be 100 mg once daily.
Study: NCT02915666

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin Combination
Description: Digoxin 0.25 mg PO daily will be given for 8-week cycles
Study: NCT04662853

Intervention type: DIAGNOSTIC_TEST
Intervention: Gut microbiota determination from feces samples.
Description: Determination of the gut microbiota composition by 16S metagenomic and building of a mathematical model, on the basis of the colonoscopies results, able to classify patients without and with color-rectal cancer-related lessions. These latter will be also classified according to the type of lession.
Study: NCT02915666

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib
Description: dabrafenib 150mg PO twice daily for 8-week cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: trametinib 2 mg PO daily for 8-week cycles
Study: NCT04048486

Intervention type: OTHER
Intervention: Developmental score according to The Ages & Stages Questionnaires®, Third Edition - ASQ®-3
Description: Ages \& Stages Questionnaires®, Third Edition (ASQ®-3) is a developmental screening tool designed for use by early educators and health care professionals. It relies on parents as experts, is easy-to-use, family-friendly and creates the snapshot needed to catch delays and celebrate milestones.

Intervention type: OTHER
Intervention: Developmental score according to The Ages & Stages Questionnaires®, Third Edition - ASQ®-3
Description: Ages \& Stages Questionnaires®, Third Edition (ASQ®-3) is a developmental screening tool designed for use by early educators and health care professionals. It relies on parents as experts, is easy-to-use, family-friendly and creates the snapshot needed to catch delays and celebrate milestones.

Intervention type: OTHER
Intervention: Physical development and General Health
Description: Physical development and General health examination

Intervention type: OTHER
Intervention: Physical development and General Health
Description: Physical development and General health examination

Intervention type: OTHER
Intervention: Developmental Red flags
Description: Developmental Red flags Questionnaires

Intervention type: OTHER
Intervention: Developmental Red flags
Description: Developmental Red flags Questionnaires
Study: NCT02422498

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: external beam radiation therapy
Description: Radiation therapy to the target tumor will be delivered with external beam radiation therapy. In metastatic cases where the intent is palliative, the dose of radiation will be 3750 cGy delivered in 15 daily fractions, 4-5 days a week. In locoregionally recurrent cases where the intent is to enhance locoregional control, the dose of radiation will be 5000 cGy delivered in 25 fractions, 4-5 days a week plus an optional 10-14 Gy boost to areas of gross tumor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Cisplatin treatment should be initiated following study registration. The dose of cisplatin is established as 25 mg/m\^2 ivpb once a week (+ 3 days) for 1-2 weeks prior to radiation. The length of one cycle of Cisplatin is 21 days.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy of Target Tumor
Description: Biopsy of the tumor to be irradiated will be performed. Fresh tissue specimens will be sent to the laboratory for performance of the MSK-HRR Assay.
Study: NCT03308916

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: transient elastography
Description: Ultrasound elastography using shear-wave elastography to measure liver stiffness as a marker of liver fibrosis. Patients with transient elastography above 8.0 kPa selected for liver biopsy to detect advanced liver fibrosis

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Enhanced liver fibrosis test
Description: Patented, commercially available algorithm of hyaluronic acid (HA), N-terminal propeptide of collagen type 3 (P3NP) and tissue inhibitor of metalloproteinase 1 (TIMP-1)

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Indirect serum markers of liver fibrosis
Description: Diagnostic markers using combination of routine liver biochemistry: age, AST, ALT, platelet count, cholesterol, GGT

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Direct serum markers of liver fibrosis
Description: Serum markers that reflect liver extracellular matrix turnover and -accumulation

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: LiverTRAIL
Description: Software that contain 199 diagnostic algorithms, containing combinations of routine tests: age, AST, albumin, alkaline phosphatase, bilirubin, GGT, INR, platelet count, cholesterol and sodium, and specialist tests: transient elastography and direct serum markers of fibrosis.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Cytokeratin 18
Description: Cytokeratin 18 from liver cell cytoskeleton; when cells undergo apoptosis, caspase-cleaved CK18 is released (M30), whereas full-length CK18 is realised during necrosis (M65)

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Omics markers
Description: Markers combining signatures of liver fibrosis and hepatic inflammation from many 'omics technologies
Study: NCT01122602

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylsalicyclic acid (Fast acting Aspirin, BAY1019036)
Description: Single dose of fast acting aspirin 2 x 325 mg = 650 mg total

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetylsalicyclic acid (Aspirin, BAYE4465)
Description: Single dose of regular aspirin 2 x 325 mg = 650 mg total

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two placebo tablets
Study: NCT00732823

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - No device worn

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Prototype device(unnamed)-A battery operated inflatable pneumatic cuffs

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Prototype device(unnamed)-A battery operated inflatable pneumatic cuffs
Study: NCT00752557

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhBMP-2/CPM injection and bisphosphonates, calcium, and vitamin D (oral bisphosphonate therapy)
Description: Single, unilateral intraosseous injection of 6mL of rhBMP-2/CPM , 1.0 mg/mL.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhBMP-2/CPM injection and bisphosphonates, calcium, and vitamin D (oral bisphosphonate therapy)
Description: Single, unilateral intraosseous injection of 6mL of rhBMP-2/CPM , 2.0 mg/mL.
Study: NCT00732823

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Prototype device(unnamed)-A battery operated inflatable pneumatic cuffs
Study: NCT01172535

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir
Description: Heat-stable tablets of 100 mg lopinavir, 25 mg ritonavir, or liquid formulation of 80 mg lopinavir, 20 mg ritonavir, dosed according to World Health Organization (WHO) pediatric weight band dosing guidelines
Study: NCT04021095

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Head protection prototype device
Description: The proposed experimental HPPD uses biocompatible material using FDMÔNylon which has high fatigue resistance, chemical resistance with impact resistance and toughness which is free of powders. It is HSA unclassified as yet and the FDMONylon is not FDA approved yet.
Study: NCT02368665

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine 5mg
Description: - Daily oral administration for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine 5mg, Candesartan cilexetil 16mg
Description: - Daily oral administration Amlodipine 5mg for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine 10mg, Candesartan cilexetil 16mg
Description: - After 8 weeks of administration, Amlodipine 10mg and Candesartan cilexetil 16mg once a day for 8 weeks
Study: NCT02008123

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Primidone
Description: Primidone is an antiepileptic used for the management of generalized tonic-clonic seizures and for the management of complex partial seizures. One of primidone's active metabolite is phenobarbital, which is a potent cytochrome P450 inducer. In this study, primidone will be used to induce CYP 1A2 in order to provide more efficient metabolism of clopidogrel to its active form
Study: NCT02959593

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VISIOR video goggles
Description: View commercially available content through the VISIOR video goggles continuously for thirty minutes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VISIOR video goggles
Description: View commercially available content through the VISIOR video goggles continuously for thirty minutes.
Study: NCT02486575

Intervention type: OTHER
Group type: OTHER
Intervention: Self-learning
Description: Every resident will train following the video instruction included in the FLS course material and related written instruction only

Intervention type: OTHER
Group type: OTHER
Intervention: Mentoring
Description: A tutor will follow each resident during learning, giving instruction, examples and any kind of suggestions.
Study: NCT03568981

Intervention type: RADIATION
Intervention: Partial breast irradiation
Description: After breast- conservating surgery, all patients are allowed to receive partial breast irradiation or whole breast irradiation after surgery according to the international guidelines and physician's discretion.

Intervention type: RADIATION
Intervention: Whole breast irradiation
Description: After breast- conservating surgery, all patients are allowed to receive partial breast irradiation or whole breast irradiation after surgery according to the international guidelines and physician's discretion.
Study: NCT00752557

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bisphosphonates, calcium, and vitamin D
Description: Oral bisphosphonate therapy
Study: NCT04072692

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hybrid rehabilitation training
Description: Hybrid rehabilitation training is modified tendon gliding exercise with median nerve mobilization.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional rehabilitation training
Description: Traditional rehabilitation training uses traditional physiotherapy, such as splint, therapeutic ultrasound and electrotherapy.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wearable anti-bowstringing orthosis (WABO)
Description: WABO is a custom-designed orthosis to restrict the bowstringing effect of the flexor tendon in the carpal tunnel.
Study: NCT00105911

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Cognitive Behavioral Therapy
Study: NCT01156480

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hydrocortisone
Description: Subjects in hydrocortisone group will receive 3mg/kg/day divided every 8 hours via IV route for 3 days, followed by 2mg/kg/day divided every 8 hours IV for 1 day, followed by 1.5mg/kg/day divided every 8 hours IV for 1 day, followed by 1mg/kg/day divided every 12 hours for 1 day, followed by 0.5mg/kg/day in single dose for one day. The first dose of study drug will be given within 6 hours of diagnosis of NEC, once informed consent is obtained, and subjects will continue to receive study drug until all doses have been given (total of 18 doses) or consent is withdrawn.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Subjects in placebo group will receive a volume of placebo equal to the hydrocortisone group, on the same dosing schedule, with doses given every 8 hours via IV route for 3 days, followed by placebo every 8 hours IV for 1 day, followed by placebo every 8 hours IV for 1 day, followed by placebo every 12 hours for 1 day, followed by placebo in single dose for one day. The first dose of study drug will be given within 6 hours of diagnosis of NEC, once informed consent is obtained, and subjects will continue to receive study drug until all doses have been given (total of 18 doses) or consent is withdrawn.
Study: NCT03573687

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Micellar Casein Protein
Description: The micellar casein protein supplement (PRO, total protein content: 30 g, 120 kcals; 30 g micellar protein) and non-caloric sensory-matched placebo (PLA, 0kcals) will be specifically formulated by Dymatize® Nutrition FrieslandCampina® and consumed in a randomized order. Participants will consume the daytime supplement 30 minutes after RT and the nighttime supplement about 30 minutes before bedtime. The supplements will be premixed, taste-matched (chocolate), and provided in opaque shaker bottles.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Micellar Casein Protein
Description: The micellar casein protein supplement (PRO, total protein content: 30 g, 120 kcals; 30 g micellar protein) and non-caloric sensory-matched placebo (PLA, 0kcals) will be specifically formulated by Dymatize® Nutrition FrieslandCampina® and consumed in a randomized order. Participants will consume the daytime supplement 30 minutes after RT and the nighttime supplement about 30 minutes before bedtime. The supplements will be premixed, taste-matched (chocolate), and provided in opaque shaker bottles.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance Exercise Training
Description: Resistance exercise training (RT) will target the full body and exercises will be performed using a barbell. Exercises will be performed in the following order: back squat, bench press, Romanian deadlift, bent-over row, shoulder press, and reverse lunges)
Study: NCT00887302

Intervention type: PROCEDURE
Intervention: Gastric Band
Description: Places a band over the upper portion of the stomach.

Intervention type: PROCEDURE
Intervention: Gastric Sleeve
Description: Stapling stomach vertically to reduce size of stomach and removal of larger curve portion of the stomach

Intervention type: PROCEDURE
Intervention: Gastrostomy Tube
Description: Tube is inserted into the stomach that delivers nutrition directly into the stomach.
Study: NCT03573687

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance Exercise Training
Description: Resistance exercise training (RT) will target the full body and exercises will be performed using a barbell. Exercises will be performed in the following order: back squat, bench press, Romanian deadlift, bent-over row, shoulder press, and reverse lunges)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance Exercise Training
Description: Resistance exercise training (RT) will target the full body and exercises will be performed using a barbell. Exercises will be performed in the following order: back squat, bench press, Romanian deadlift, bent-over row, shoulder press, and reverse lunges)
Study: NCT02470221

Intervention type: OTHER
Intervention: Applying goal-directed fluid therapy by continuous hemodynamic monitoring system
Description: Applying continuous hemodynamic monitoring system ( Vigileo/Flotrac) to monitor Stroke Volume Variation and Cardiac Output and further manage intra-operative fluid therapy.

Intervention type: OTHER
Intervention: Conventional fluid therapy
Description: Applying conventional fluid therapy according to Peking Union Medical College Hospital standard.
Study: NCT02289664

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MAC
Description: Direct-Laryngoscopy
Study: NCT03935321

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NG-101
Description: 6 intrathecal bolus injections, each of 45mg
Study: NCT02289664

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MAC
Description: Direct-Laryngoscopy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coopdech
Description: Video-Laryngoscopy -1

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coopdech
Description: Video-Laryngoscopy -1

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CoPilot
Description: Video-Laryngoscopy -2

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CoPilot
Description: Video-Laryngoscopy -2

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intubrite
Description: Video-Laryngoscopy -3

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intubrite
Description: Video-Laryngoscopy -3
Study: NCT04537793

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ELX/TEZ/IVA
Description: Fixed dose combination granules for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ELX/TEZ/IVA
Description: Fixed dose combination granules for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVA
Description: Granules for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVA
Description: Granules for oral administration.
Study: NCT02976337

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naloxone
Description: active drug infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: placebo comparator
Study: NCT02859246

Intervention type: DRUG
Group type: OTHER
Intervention: Mucinex®
Description: Mucinex®
Study: NCT02271464

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maintenance:BEVACIZUMAB
Description: Patients will be randomly assigned to receive induction chemotherapy with the G.O.N.O. FOLFOXIRI regimen plus bevacizumab:~* BEVACIZUMAB 5 mg/kg over 30 minutes, day 1~* IRINOTECAN 165 mg/sqm IV over 1-h, day 1~* OXALIPLATIN 85 mg/sqm IV over 2-h, day 1~* L-LEUCOVORIN 200 mg/sqm IV over 2-h, day 1~* 5-FLUOROURACIL 3200 mg/sqm IV 48-h continuous infusion, starting on day 1~with cycles repeated every 2 weeks for 4 months (8 cycles), followed after 2 weeks by (if no progression occurs):~- BEVACIZUMAB 7.5 mg/kg over 30 minutes, day 1 (every three weeks)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maintenance:BEVACIZUMAB+CAPECITABINE+CYCLOPHOSPHAMIDE
Description: Patients will be randomly assigned to receive induction chemotherapy with the G.O.N.O. FOLFOXIRI regimen plus bevacizumab:~* BEVACIZUMAB 5 mg/kg over 30 minutes, day 1~* IRINOTECAN 165 mg/sqm IV over 1-h, day 1~* OXALIPLATIN 85 mg/sqm IV over 2-h, day 1~* L-LEUCOVORIN 200 mg/sqm IV over 2-h, day 1~* 5-FLUOROURACIL 3200 mg/sqm IV 48-h continuous infusion, starting on day 1~with cycles repeated every 2 weeks for 4 months (8 cycles), followed after 2 weeks by (if no progression occurs):~* BEVACIZUMAB 7.5 mg/kg over 30 minutes, day 1 (every three weeks),~* CAPECITABINE 500 mg/tid orally, continuously,~* CYCLOPHOSPHAMIDE 50 mg/day orally, continuously.
Study: NCT00231777

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: MK0517
Description: a single administration of 40 mg MK0517 by IV immediately prior to surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: ondansetron
Description: a single administration of 4 mg ondansetron by IV immediately prior to surgery
Study: NCT03658005

Intervention type: OTHER
Intervention: Blood sample
Description: 3 blood samples, for a maximum of 60mL, will be taken at 0-3h, 3-6h and \>6h, between two doses of ticagrelor (taken at 0 and 12 hours).